MSN: RCA : menace de fermeture de la Cour pénale spéciale (Amnesty)
RCA : menace de fermeture de la Cour pénale spéciale (Amnesty) ( 17 octobre 2025 | 17:37 ) Avec la menace de fermeture de la Cour pénale spéciale, des milliers de victimes de deux décennies de conflit ...
After 10 Years of Hard Work, COUR Treads Into Pharma’s ... - BioSpace
Reprogramming the immune system. Restoring lives. At COUR, we develop targeted therapies that incite calm within the immune system and help restore the health of people suffering from autoimmune diseases.
Roche’s Genentech unit has tapped Cour to help develop and commercialize the biotech’s bespoke tolerogenic nanoparticle treatments for autoimmune diseases, Cour said Tuesday.
Coursera Inc (COUR) reports a 9% revenue increase and sets a first-quarter record with 7.6 million new learners, while focusing on AI-driven platform enhancements.
Get real-time Coursera (COUR) stock price, charts, news, and analyst ratings on Benzinga. Access forecasts, historical data, and expert insights to inform your investment decisions.
COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart was approved for the disease in 2021 while Johnson & Johnson has filed for approval of nipocalimab and Amgen recently trumpeted positive late-stage results.
COUR posts steady revenue growth above 13% over three years, but profit margins remain negative, weighing on sentiment. Active traders are watching whether COUR can reclaim the $6 area or breaks under $5 as the next key move.
Coursera Inc. (COUR) reported first-quarter 2026 results.Revenue rose 9.2% year over year to $195.7
Get real-time Coursera Inc (COUR) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.